psilocybin
Brain-MGF: Multimodal Graph Fusion Network for EEG-fMRI Brain Connectivity Analysis Under Psilocybin
Yap, Sin-Yee, Noman, Fuad, Loo, Junn Yong, Stoliker, Devon, Khajehnejad, Moein, Phan, Raphaël C. -W., Dowe, David L., Razi, Adeel, Ting, Chee-Ming
Phan 1, David L. Dowe 2, Adeel Razi 3,, and Chee-Ming Ting 1, 1 School of Information Technology, Monash University Malaysia, Malaysia 2 Department of Data Science and AI, Faculty of Information Technology, Monash University, Australia 3 Turner Institute for Brain and Mental Health, School of Psychological Sciences, Monash University, Australia ABSTRACT Psychedelics, such as psilocybin, reorganise large-scale brain connectivity, yet how these changes are reflected across electrophys-iological (electroencephalogram, EEG) and haemodynamic (functional magnetic resonance imaging, fMRI) networks remains unclear. For each modality, we construct graphs with partial-correlation edges and Pearson-profile node features, and learn subject-level embeddings via graph convolution. An adaptive softmax gate then fuses modalities with sample-specific weights to capture context-dependent contributions. Fusion improves over unimodal and nonadaptive variants, achieving 74.0% accuracy and 76.5% F1 score on meditation, and 76.0% accuracy with 85.8% ROC-AUC on rest. UMAP visualisations reveal clearer class separation for fused em-beddings.
- Oceania > Australia (0.44)
- Asia > Malaysia (0.44)
- North America > Canada > Quebec > Montreal (0.04)
- Europe > Switzerland (0.04)
- Health & Medicine > Therapeutic Area > Neurology (1.00)
- Health & Medicine > Health Care Technology (1.00)
- Health & Medicine > Diagnostic Medicine > Imaging (1.00)
- Health & Medicine > Therapeutic Area > Psychiatry/Psychology (0.88)
People are using AI to 'sit' with them while they trip on psychedelics
Peter--who asked to have his last name omitted from this story for privacy reasons--is far from alone. A growing number of people are using AI chatbots as "trip sitters"--a phrase that traditionally refers to a sober person tasked with monitoring someone who's under the influence of a psychedelic--and sharing their experiences online. It's a potent blend of two cultural trends: using AI for therapy and using psychedelics to alleviate mental-health problems. But this is a potentially dangerous psychological cocktail, according to experts. While it's far cheaper than in-person psychedelic therapy, it can go badly awry.
- North America > United States > Oregon (0.07)
- North America > United States > Colorado (0.05)
Scientists say they may have discovered origin of consciousness - and it's a theory popularized by Joe Rogan
The birth of human consciousness may have truly been magic. Scientists have claimed that the consumption of the fungi psilocybin, also known as'magic mushrooms,' influenced pre-human hominids' brains six million years ago. They analyzed dozens of studies involving psilocybin and consciousness, finding the fungi increased connectivity between networks in the frontal brain region associated with expressive language, decision-making and memory. These'significant neurological and psychological effects' may have been the catalase ancient ancestors to interact with each other and the environment - spurring consciousness among our species. The idea that magic mushrooms sparked the pivotal point in humans has been touted by podcaster Joe Rogan, who has referenced the'Stoned Ape Theory' on his show multiple times.
British firm starts trials of psychedelic drug to treat depression
People suffering with depression could soon have a new treatment, in the form of a drug based on a common psychedelic substance found in plants, developers claim. The first patient dosing of the drug, based on the compound DMT (N-Dimethyltryptamine), is being given to'healthy brained' first time drug users in a clinical trial that will examine the impact the substance has on the brain. If successful, the second stage of the trial will see the team experiment with different dosing levels and strategies and eventually treat people with depression. It works by sending the patient on a hallucinogenic trip that acts to'break down' blockages in the mind, that can then be restored with a course of therapy. British biotech firm Small Pharma are running the trial, and CEO Peter Rands told MailOnline said it had the potential to help people not supported by current drugs.
Its (Almost) the End of the World As We Know It
To be fully transparent, I started writing this post in late 2018 in an attempt to detail my own "Things you should be focused on as an investor/consumer in 2019," but the year got ahead of me as interesting projects materialized and so too did my resolution to write more! Some of these projects have already progressed further than I had imagined - I have been fortunate enough to have spent the last two years working, researching & exploring areas that I find most pivotal to improving our quality of life, and we seem to be at an interesting inflection point among all. There are countless applications of Artificial Intelligence either already deployed or in development, with many more envisioned every day. I am most excited for AI that will automate and assist the best interests of the individual: personalized recommendations. I believe said recommendations, those pesky things that currently inundate our platforms with little explanation, should be more transparent and easier to understand.
- North America > United States > New York (0.05)
- North America > United States > California (0.05)
- North America > Canada (0.05)
- (2 more...)
- Health & Medicine > Pharmaceuticals & Biotechnology (1.00)
- Transportation (0.97)
- Health & Medicine > Therapeutic Area (0.96)
- (2 more...)
What causes hallucinations: Mouse study uncovers unexpected changes in the brain's signaling
Scientists may finally be close to understanding the mechanisms behind hallucination. Despite the dramatic perceptual changes that take place during a bout of hallucination, what exactly happens in the brain during these moments has long been a mystery. A new study on drugged mice has found that the phenomena associated with these episodes may be the result of reduced signaling in the visual cortex – not an increase, as was expected. The images revealed that even after taking the drug, the signals being sent were largely similar to those seen in its absence, indicating that the information itself does not change. 'You might expect visual hallucinations would result from neurons in the brain firing like crazy, or by mismatched signals,' says senior author Cris Niell, an associate professor and member of the Institute of Neuroscience at the University of Oregon.
Could artificial intelligence get depressed and have hallucinations?
A hallucinating artificial intelligence might see something like this product of Google's Deep Dream algorithm. As artificial intelligence (AI) allows machines to become more like humans, will they experience similar psychological quirks such as hallucinations or depression? And might this be a good thing? Last month, New York University in New York City hosted a symposium called Canonical Computations in Brains and Machines, where neuroscientists and AI experts discussed overlaps in the way humans and machines think. Zachary Mainen, a neuroscientist at the Champalimaud Centre for the Unknown, a neuroscience and cancer research institute in Lisbon, speculated that we might expect an intelligent machine to suffer some of the same mental problems people do.
- North America > United States > New York (0.47)
- Europe > Portugal > Lisbon > Lisbon (0.25)
- Health & Medicine > Therapeutic Area > Neurology (1.00)
- Health & Medicine > Therapeutic Area > Psychiatry/Psychology (0.94)
3 Exciting Biotech Trends to Watch Closely in 2017
As I start to look at the emerging trends of 2017 from the vantage of IndieBio, where we see hundreds of biotech startup applications and technologies per year, a few key themes are already emerging. Even as political landscapes change, science and technology continue to push forward. Most of us have seen science fiction shows that show future doctors regrowing and replacing entire organs. That fiction is now becoming a reality with cell therapies from companies like Juno (curing two infants with leukemia of their previously treatment resistant cancers with engineered T-cells), induced pluripotent stem cells (iPS) pioneered by the Nobel prize winning scientist, Shinya Yamanaka that can become any cell in the body, growing organoids (mini organs with some function of a fully grown organ like the stomach organoids grown by researchers in Ohio), and entirely re-grown organs. There are a plethora of biotechs focused on developing the next generation of regenerative therapies.
- North America > United States > Ohio (0.25)
- Asia > Taiwan (0.05)
2017 Biotech Trends–Regrown Organs, Augmented Brains, and AI Diagnosis - Techonomy
Imaging and understanding the brain is getting so good we are on the cusp of truly enhancing it. This article originally appeared on SOSV.) As I start to look at the emerging trends of 2017 from the vantage of IndieBio, where we see hundreds of biotech startup applications and technologies per year, a few key themes are already emerging. Even as political landscapes change, science and technology continue to push forward. Most of us have seen science fiction shows that show future doctors regrowing and replacing entire organs.
- North America > United States > Ohio (0.05)
- Asia > Taiwan (0.05)
LSD 'microdosing' trend can put your life at risk
Growing numbers of successful Silicon Valley entrepreneurs are'microdosing' on LSD at work each day. The drug has been shown to make users more relaxed, creative and focused. But is running the risk of arrest or mental health issues worth the reported benefits? In this piece for The Conversation, University of Cambridge scientists Barbara Sahakian, Camilla d'Angelo and George Savulich how the trend could be putting lives at risk. Researchers in Germany and the UK carried out trials in which participants were asked to name a number of pictures, either under the influence of acid or taking a placebo.
- North America > United States > California (0.27)
- Europe > United Kingdom > England > Cambridgeshire > Cambridge (0.25)
- Europe > Germany (0.25)